Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living With Obesity or Overweight With Comorbidity

NCT06579092 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06579092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06579092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living With Obesity or Overweight With Comorbidity
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 8, 2024
Completion date
November 21, 2025
Enrollment
310 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

obesity or overweight